Advances in sequencing technology have helped us to gain insights into the pathogenesis of AML and accordingly develop new drug targets and formulate risk stratification, such as Fms-like tyrosine kinase 3 - internal tandem duplication (FLT3-ITD), Isocitrate dehydrogenase(IDH) mutations (3–5). The gene discussed is FLT3; the disease is acute myeloid leukemia.